Presence of extrahepatic extension of disease

Prior locoregional therapy to target lesions is not allowed. History of curative locoregional therapy is allowed provided the following are met: 1) previously treated tumor is not viable without evidence of residual disease for at least 12 months, and 2) patient has not received local therapy in the past 12 months.

Known fibrolamellar HCC or combined HCC-cholangiocarcinoma histology

History of hepatic encephalopathy

Severe ascites requiring paracentesis in the past 3 months

Subjects may not be receiving any other investigational agents for the treatment of the cancer under study

Prior significant bleeding event in the past 3 months that may pose a surgical risk

History of trauma or major surgery within 28 days prior to the first dose of study drug administration. (Tumor biopsy or placement of central venous access catheter (eg, port or similar) is not considered a major surgical procedure)

Underlying medical conditions that, in the investigator's opinion, will make the administration of study drugs hazardous, including but not limited to:

1. Autoimmune interstitial lung disease (lymphangitic spread of cancer is not disqualifying or stable/chronic lung disease that is not likely to be autoimmune in nature and progressive),
2. Active viral, bacterial, or fungal infections requiring parenteral treatment within 14 days of the initiation of study drugs,
3. Clinically significant cardiovascular disease,
4. A condition that may obscure the interpretation of toxicity determination or AEs,
5. History of prior bone marrow and/or solid-organ transplantation

Hypersensitivity to IV contrast; not suitable for pre-medication

Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past year (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), with the following exceptions:

1. Autoimmune diseases with only dermatologic involvement such as eczema, vitiligo, lichen chronicus, or resolved childhood asthma/atopy which involves less than 10% of the body surface area and symptoms are well controlled on topical treatments without recent exacerbations requiring other therapies
2. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for thyroid, adrenal or pituitary insufficiency) is not considered a form of systemic treatment
3. Participants with asthma who require intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroid injections will not be excluded from this study

Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg/day prednisone equivalent) or other immunosuppressive medications within 14 days of study administration. Inhaled or topical steroids and adrenal replacement doses ≤10 mg/day prednisone equivalents are permitted in the absence of autoimmune disease.

Prior malignancy that required systemic treatment within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer. Patients with a cancer history with a low risk of recurrence or progression may be enrolled as determined by the principal investigator.

Prisoners or subjects who are involuntarily incarcerated

Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after contraception and until the termination of gestation, confirmed by a positive hCG (Human chorionic gonadotropin) laboratory test

Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

Evidence of bleeding diathesis or significant coagulopathy

Current use of full dose anticoagulant use which cannot be temporarily discontinued for surgery

Receipt of live vaccinations within 30 days of first treatment day